October 2025 in “Journal of Clinical Medicine” Patients with certain baseline characteristics are more likely to benefit early from baricitinib for alopecia areata.
September 2022 in “Reactions Weekly”
25 citations
,
July 2024 in “Frontiers in Pharmacology” Rimegepant causes more nausea and skin issues, while ubrogepant causes more muscle issues; personalized treatment is important.
February 2010 in “Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature” Finasteride can cause skin reactions, so dermatologists should be aware.
Naproxen can cause serious lung issues, but high-dose aspirin might be safer.
March 2023 in “Clinical Toxicology” September 2025 in “Cosmetics” Genetic profiling can improve androgenetic alopecia treatment by predicting drug response and minimizing side effects.
The model predicts minoxidil's effectiveness and side effects better than traditional methods.
3 citations
,
January 2008 in “Drug Safety” October 2025 in “Figshare” Deuruxolitinib effectively treats alopecia areata but may cause manageable side effects.
August 2017 in “Journal of Pharmacy Practice and Research” Risk analysis is important for safely adjusting pharmaceutical formulas while maintaining their quality and effectiveness.
8 citations
,
April 2018 in “Journal of the European Academy of Dermatology and Venereology” Certain genetic variations can make people more likely to experience hair loss and low white blood cell count from azathioprine.
5 citations
,
January 2024 in “BMC Cancer” Anthracycline and taxane chemotherapy cause significant side effects like fatigue, vomiting, nausea, nerve damage, joint pain, and hair loss in breast cancer patients.
December 2025 in “Cureus” Using 5α-reductase inhibitors for hair loss may increase the risk of dry eye disease.
January 2025 in “Journal of Crohn s and Colitis” Tofacitinib is effective and safe for elderly patients with ulcerative colitis.
June 2026 in “Frontiers in Oncology” Ipilimumab can cause various adverse events in elderly patients, especially affecting the gastrointestinal and endocrine systems.
April 2015 in “Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature” The safety of the hair loss drug finasteride is unclear due to inadequate reporting in clinical trials.
142 citations
,
March 2019 in “Frontiers in Cellular Neuroscience” The document concludes that adenosine receptor agonists have potential for treating various conditions, but only a few are approved due to challenges like side effects and the need for selective activation.
2 citations
,
May 2024 in “International Journal of Medical Arts” Diphenylcyclopropenone (DPCP) is more effective than anthralin for treating resistant alopecia areata.
1 citations
,
May 2025 in “The Journal of Rheumatology” Upadacitinib may help treat difficult cases of systemic lupus erythematosus.
9 citations
,
October 2019 in “Dermatologic Therapy” Oral tofacitinib has a moderate success rate and is generally safe for treating hair loss in some patients.
33 citations
,
May 2017 in “Journal of Clinical Oncology” ETC-159 was safe up to 30 mg, but no tumor shrinkage was seen.
1 citations
,
July 2021 in “Current nanomedicine” The new gel formulation for Acitretin improves topical delivery and reduces oral toxicity.
3 citations
,
April 2025 in “Journal of Clinical Epidemiology” Non-blinded assessors tend to overestimate effects in trials by about 29%.
Some side effects of breast cancer chemotherapy last longer than others, and patient feedback can help improve care.
February 2013 in “Journal of The American Academy of Dermatology” Using hair loss drugs finasteride and dutasteride may cause sexual side effects.
17 citations
,
June 2017 in “Journal of pharmaceutical sciences” Researchers developed a nanomedicine for acne treatment that delivers medication with less irritation and is non-irritating for oily skin.
4-(Ethoxycarbophenyl) retinamide is much less toxic than other retinoids.
October 2023 in “Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy” New, eco-friendly methods accurately measure TDF and FNS in a new urologic medication.
2 citations
,
May 2025 in “Frontiers in Pharmacology” Aromatase inhibitors can cause skin issues, especially with anastrozole and exemestane, so monitoring is important.